A blood test detecting circulating tumor DNA post-surgery can help identify colorectal cancer patients with liver metastases who are most likely to benefit from adjuvant chemotherapy, according to data from the Phase II GALAXY study.
The patent covers a gene-expression profiling method designed to identify patients most likely to respond to the investigational therapy stenoparib through 2042.
The test detect signs of colorectal cancer and precancerous growths using a home collection kit.
Labcorp studies report new blood-based tools, including the Metabolic Vulnerability Index, may improve risk assessment for MASLD and MASH, offering enhanced prediction of adverse liver outcomes, according to recent peer-reviewed research.
The point-of-care assay provides results in 15 minutes and received a waiver for use in decentralized settings.
A simplified test of HDL's ability to remove cholesterol was associated with high-risk coronary plaques in a study of 61 patients.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures enzyme activity in plasma to help clinicians identify acute ischemic stroke, which is often missed by standard imaging.
The study highlights the role of brain-derived nanoparticles in identifying the disease through minimally invasive testing.
Research suggests that only 12% of men receiving testosterone prescriptions underwent appropriate testing.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.